IMUNON Reorganizes for Phase 3 Ovarian Cancer Study, Khursheed Anwer to Retire

Imunon has restructured to focus on its Phase 3 ovarian cancer study, eliminating expenses not essential to the trial. The company's Phase 3 study enrollment remains ahead of schedule, advancing it toward a future BLA filing. Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at Imunon.